Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian Countries

Frontiers in Pharmacology

Volumn 8, Issue JAN, 2018, Pages

  Bochenek, Tomasz ^a   Abilova, Vafa ^b   Alkan, Ali ^c   Asanin, Bogdan ^d   Beriain, Iñigo de Miguel ^e   Besovic, Zeljka ^f   Bonanno, Patricia Vella ^g   Bucsics, Anna ^h   Davidescu, Michal ⁱ   De Weerdt, Elfi ^j   Duborija Kovacevic, Natasa ^d   Fürst, Jurij ^k   Gaga, Mina ^l   Gailite, Elma ^m   Gulbinovič, Jolanta ^n,o   Gürpinar, Emre U ^c   Hankó, Balázs ^p   Hargaden, Vincent ^q   Hotvedt, Tor A ^r   Hoxha, Iris ^s   Huys, Isabelle ^j   Inotai, Andras ^t,u   Jakupi, Arianit ^v   Jenzer, Helena ^w,x   Joppi, Roberta ^y   Laius, Ott ^z   Lenormand, Marie Camille ^aa   Makridaki, Despina ^ab,ac   Malaj, Admir ^s   Margus, Kertu ^z   Marković Peković, Vanda ^ad,ae   Miljković, Nenad ^af   de Miranda, João L ^ag,ah   Primožič, Stanislav ^ai   Rajinac, Dragana ^aj   Schwartz, David G ^ak   Šebesta, Robin ^al   Simoens, Steven ^j   Slaby, Juraj ^al   Sović Brkičić, Ljiljana ^am   Tesar, Tomas ^an   Tzimis, Leonidas ^ao   Warmińska, Ewa ^ap   Godman, Brian ^g,aq,ar   more..

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Ministry of Health   (Azerbaijan)

^c Turkish Medicines and Medical Devices Agency   (Turkey)

^d UNIVERSITY OF MONTENEGRO   (Montenegro)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f Montenegrin Agency for Drugs and Medical Devices   (Montenegro)

^g UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^h Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)   (Belgium)

ⁱ CLALIT HEALTH SERVICES   (Israel)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k Health Insurance Institute   (Slovenia)

^l Sixth Pulmonary Clinic   (Greece)

^m Virology Department of Laboratory   (Latvia)

ⁿ VILNIUS UNIVERSITY   (Lithuania)

^o State Medicine Control Agency of Lithuania   (Lithuania)

^p SEMMELWEIS UNIVERSITY   (Hungary)

^q UNIVERSITY COLLEGE DUBLIN   (Ireland)

^r Norwegian Medicines Agency   (Norway)

^s University of Medicine   (Albania)

^t Syreon Research Institute   (Hungary)

^u EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^v UNIVERSITY FOR BUSINESS AND TECHNOLOGY   (Serbia)

^w BERN UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

^x University of Z Urich   (Switzerland)

^y Local Health Unit of Verona   (Italy)

^z State Agency of Medicines   (Estonia)

^aa Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^ab Panhellenic Association of Hospital Pharmacists   (Greece)

^ac National Organization for Medicines (EOF)   (Greece)

^ad MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^ae UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^af Institute for Orthopaedic Surgery Banjica   (Serbia)

^ag POLYTECHNIC INSTITUTE OF PORTALEGRE   (Portugal)

^ah INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^ai Agency for Medicinal Products and Medical Devices   (Slovenia)

^aj CLINICAL CENTER OF SERBIA   (Serbia)

^ak BAR ILAN UNIVERSITY   (Israel)

^al State Institute for Drug Control   (Czech Republic)

^am Croatian Health Insurance Agency   (Croatia)

^an Faculty of Natural Sciences   (Slovakia)

^ao Chania General Hospital   (Greece)

^ap Group of Dentons US LLP   (Poland)

^aq KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ar UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

more..

Author keywords

Drug shortage; Europe; European Union; Health care system; Legislation; Organizational framework; Pharmaceutical policy; Western Asia

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; ASIA; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; DRUG MARKETING; DRUG SHORTAGE; ETHICS; EUROPE; EVALUATION STUDY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; LAW; MONITORING; OBSERVATIONAL STUDY; PATIENT CARE; POLITICS; PUBLIC HEALTH PROBLEM; RETROSPECTIVE STUDY; SOCIETY; UNLICENSED DRUG USE; WORKLOAD;

EID: 85041119280     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00942     Document Type: Article

References (60)

1. Alsheikh, M., Seoane-Vazquez, E., Rittenhouse, B., Fox, E. R., and Fanikos, J. (2016). A comparison of drug shortages in the Hospital Setting in the United States and Saudi Arabia: an exploratory analysis. Hosp. Pharm. 51, 370-375. doi: 10.1310/hpj5105-370
2. American Society of Anesthesiologists (2017). Drug Shortages. Available online at: https://www.asahq.org/advocacy/federal-activities/regulatory-activity/drug-shortages (cited August 28, 2017)
3. Awad, H., Al-Zu'bi, Z. M. F., and Abdallah, A. B. (2016). A quantitative analysis of the causes of drug shortages in jordan: a supply chain perspective. Int. Bus. Res. 9:53. doi: 10.5539/ibr.v9n6p53
4. Birgli, A. G. (2013). An Evaluation of Medicines Shortages in Europe with More In-Depth Review of These in France, Greece, Poland, Spain and the United Kingdom. Available online at: http://static.correofarmaceutico.com/docs/2013/10/21/evaluation.pdf
5. Bocquet, F., Degrassat-Théas, A., Peigné, J., and Paubel, P. (2017). The new regulatory tools of the 2016 Health Law to fight drug shortages in France. Health Policy 121, 471-476. doi: 10.1016/j.healthpol.2017.03.007
6. Bogaert, P., Bochenek, T., Prokop, A., and Pilc, A. (2015). A qualitative approach to a better understanding of the problems underlying drug shortages, as viewed from Belgian, French and the European Union's perspectives. PLoS ONE 10:e0125691. doi: 10.1371/journal.pone.0125691
7. Butterfield, L., Cash, J., and Pham, K. (2015). Position statement drug shortages and implications for pediatric patients. J. Pediatr. Pharmacol. Ther. 20, 149-152. doi: 10.5863/1551-6776-20.2.149
8. Cacace, M., Ettelt, S., Mays, N., and Nolte, E. (2013). Assessing quality in cross-country comparisons of health systems and policies: Towards a set of generic quality criteria. Health Policy 112, 156-162. doi: 10.1016/j.healthpol.2013.03.020
9. Costelloe, E. M., Guinane, M., Nugent, F., Halley, O., and Parsons, C. (2014). An audit of drug shortages in a community pharmacy practice. Ir. J. Med. Sci. 435-440. doi: 10.1007/s11845-014-1139-7
10. De Weerdt, E., De Rijdt, T., Simoens, S., Casteels, M., and Huys, I. (2017a). Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study. PLoS ONE 12:e0174556. doi: 10.1371/journal.pone.0174556
11. De Weerdt, E., Simoens, S., Casteels, M., and Huys, I. (2015a). Toward a European definition for a drug shortage: a qualitative study. Front Pharmacol. 6:253. doi: 10.3389/fphar.2015.00253
12. De Weerdt, E., Simoens, S., Casteels, M., and Huys, I. (2017b). Clinical, economic and policy implications of drug shortages in the European union. Appl. Health Econ. Health Policy 15, 441-445. doi: 10.1007/s40258-016-0264-z
13. De Weerdt, E., Simoens, S., Casteels, M., and Huys, I. (2017c). Time investment in drug supply problems by flemish community pharmacies. Front Pharmacol. 8:568. doi: 10.3389/fphar.2017.00568
14. De Weerdt, E., Simoens, S., Hombroeckx, L., Casteels, M., and Huys, I. (2015b). Causes of drug shortages in the legal pharmaceutical framework. Regul. Toxicol. Pharmacol. 71, 251-258. doi: 10.1016/j.yrtph.2015.01.005
15. Desabastecimientos de Medicamentos: Un Problema Sin Resolver (2015). INFAC, Inf Farmacoter la Comarc, Vol. 23. Available online at: https://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_infac/es_cevime/adjuntos/INFAC_Vol_23_N_7_Desabastecimientos.pdf
16. Dill, S., and Ahn, J. (2014). Drug shortages in developed countries-Reasons, therapeutic consequences, and handling. Eur. J. Clin. Pharmacol. 70, 1405-1412. doi: 10.1007/s00228-014-1747-1
17. European Association of Hospital Pharmacists (EAHP) secretariat (2014). Medicines Shortages in European Hospitals. Full Rep, 1-46
18. European Association of Pharmaceutical Industries and Associations (2014). Policy Proposals to Minimise Medicine Supply Shortages in Europe. Available online at: https://efpia.eu/media/15427/policy-proposals-to-minimise-medicine-supply-shortages-in-europe-march-2014.pdf
19. European Commission Standard Eurobarometer (2017). Key Trends. Available online at: http://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/search/eurobarometer/surveyKy/2142
20. European Medicines Agency (2017). Shortages Catalogue. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000376.jsp&mid=WC0b01ac05807477a6
21. Ferrario, A., Araja, D., Bochenek, T., Catic, T., Dankó, D., Dimitrova, M., et al. (2017). The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics 35, 1271-1285. doi: 10.1007/s40273-017-0559-4
22. Fox, E. R., and Tyler, L. S. (2017). Potential association between drug shortages and high-cost medications. Pharmacotherapy 37, 36-42. doi: 10.1002/phar.1861
23. Glynn, D. (2006). The effects of parallel trade on affordable access to medicines. Eurohealth 15, 1-5
24. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010). Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722. doi: 10.1586/erp.10.72
25. Godman, B., Wettermark, B., van Woerkom, M., Fraeyman, J., Alvarez-Madrazo, S., Berg, C., et al. (2014). Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 5:106. doi: 10.3389/fphar.2014.00106
26. Goldsack, J. C., Reilly, C., Bush, C., McElligott, S., Bristol, M. N., Motanya, U. N., et al. (2014). Impact of shortages of injectable oncology drugs on patient care. Am. J. Heal. Pharm. 71, 571-578. doi: 10.2146/ajhp130569
27. Government of Montenegro-Ministry of Health (2011). Law on Medicines, Article 45. Podgorica: Official Gazette of Montenegro No. 56/11
28. Health Products Regulatory Authority (2016). Health Products Regulatory Authority Strategic Plan 2016-2020
29. Health Products Regulatory Authority (2017). HPRA Homepage. Available online at: http://www.hpra.ie/homepage/about-us
30. Heiskanen, K., Ahonen, R., Kanerva, R., Karttunen, P., and Timonen, J. (2017). The reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland. PLoS ONE 12:e0179479. doi: 10.1371/journal.pone.0179479
31. Hungarian Minister of Health (2004). Regulation of the Minister of Health 32/2004
32. Israel's Ministry of Health-Pharmaceutical Administration (2011). Transfer of Information and Management of Crises Related to the Product Procedure. Available online at: https://www.health.gov.il/hozer/DR_84.pdf
33. Kanavos, P., Costa-Font, J., Merker, S., and Gemmill, M. (2004). The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis. London School of Economics Special Research Paper
34. Kanavos, P., Gross, D., and Taylor, D. (2006). Parallel Trading in Medicines: Europe's Experience and Its Implications for Commercial Drug Importation in the United States. Available online at: http://assets.aarp.org/rgcenter/health/2005_07_trade.pdf
35. Kavanagh, J. (2017). How Pharmaceutical Supply Chains Can Be Managed to Minimise the Number of Medicines Shortages, Unpublished Master's thesis, University College Dublin, Ireland
36. King of Spain (2015). Royal Legislative Decree 1/2015, of July 24, approving the consolidated text of the Law on Guarantees and Rational Use of Medicines and Medical Devices
37. Lipworth, W., and Kerridge, I. (2013). Why drug shortages are an ethical issue. Austr. Med. J. 6, 556-559. doi: 10.4066/AMJ.2013.1869
38. Malmström, R. E., Godman, B. B., Diogene, E., Baumgärte, C., Bennie, M., Bishop, I., et al. (2013). Dabigatran-A case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 4:39. doi: 10.3389/fphar.2013.00039
39. Mazer-Amirshahi, M., Goyal, M., Umar, S. A., Fox, E. R., Zocchi, M., Hawley, K. L., et al. (2017). U.S. drug shortages for medications used in adult critical care (2001-2016). J. Crit. Care. 41, 283-288. doi: 10.1016/j.jcrc.2017.06.005
40. McBride, A., Holle, L. M., Westendorf, C., Sidebottom, M., Griffith, N., Muller, R. J., et al. (2013). National survey on the effect of oncology drug shortages on cancer care. Am. J. Heal. Pharm. 70, 609-617. doi: 10.2146/ajhp120563
41. McLaughlin, M. M., and Skoglund, E. W. (2015). Drug shortages and patient safety. J. Infus. Nurs. 38, 205-208. doi: 10.1097/NAN.0000000000000101
42. McLaughlin, M., Kotis, D., Thomson, K., Harrison, M., Fennessy, G., Postelnick, M., et al. (2013). Effects on patient care caused by drug shortages: a survey. J. Manag. Care Pharm. 19, 783-788. doi: 10.18553/jmcp.2013.19.9.783
43. Moon, J. C., Godman, B., Petzold, M., Alvarez-Madrazo, S., Bennett, K., Bishop, I., et al. (2014). Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications. Front Pharmacol. 5:219. doi: 10.3389/fphar.2014.00219
44. Morrison, A. (2011). Drug Supply Disruptions [Environmental Scan Issue 17]. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available online at: https://www.cadth.ca/drug-supply-disruptions
45. Office UGA (2016). Generic Drugs under Medicare-Part D Generic Drug Prices Declined Overall, But Some Had Extraordinary Price Increases, GAO-16-706. 1-46. Available online at: www.gao.gov
46. Pauwels, K., Huys, I., Casteels, M., and Simoens, S. (2014). Drug shortages in European countries: a trade-offbetween market attractiveness and cost containment? BMC Health Serv Res. 14:438. doi: 10.1186/1472-6963-14-438
47. Pauwels, K., Simoens, S., Casteels, M., and Huys, I. (2015). Insights into european drug shortages: a survey of hospital pharmacists. PLoS ONE 10:e0119322. doi: 10.1371/journal.pone.0119322
48. Pfeffer, K., and Mozolová, B. (2018). Re-export of drugs in the Slovak Republic vol. 2-the Act [Internet]. Available: https://www.twobirds.com/en/news/articles/2017/uk/ils/re-export-of-drugs-in-the-slovak-republic-vol-2-the-act
49. Schweitzer, S. O. (2013). How the US Food and Drug Administration can solve the prescription drug shortage problem. Am. J. Public Health. 103, 10-14. doi: 10.2105/AJPH.2013.301239
50. Slovak Parliament (2011). Act No. 362/2011 Coll. on Medicinal Products and Medical Devices and Amending Certain Acts, as Amended (Slovakian: Zákon c. 362/2011 Z. z. o Liekoch a Zdravotníckych Pomôckach a o Zmene a Doplnení Niektorých Zákonov). Available online at: http://www.zakonypreludi.sk/zz/2011-362
51. The Parliamentary Assembly of Bosnia and Herzegovina (2008). Law on Medicinal Products and Medical Devices. Official Gazzette of B&H, No. 58: 2008. Bosnia and Herzegovina
52. United States Government Accountability Office Report (2014). Drug shortages. Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability. Available online at: http://www.gao.gov/assets/670/660785.pdf
53. Vella Bonanno, P., and Gavril, F. (2011). Seven years of EU Pharmaceutical Regulation in Malta. WHO Drug Inf. 25, 341-412
54. Ventola, C. L. (2011). The drug shortage crisis in the United States: causes, impact, and management strategies. P T. 36, 740-757
55. Voncina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., et al. (2011). Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479. doi: 10.1586/erp.11.42
56. Walker, J., Chaar, B. B., Vera, N., Pillai, A. S., Lim, J. S., Bero, L., et al. (2017). Medicine shortages in Fiji: a qualitative exploration of stakeholders' views. PLoS ONE 12:e0178429. doi: 10.1371/journal.pone.0178429
57. Wenzel, R. (2015). Drug Shortages and Tipping Points. Headache J. Head Face Pain. 55, 1294-1295. doi: 10.1111/head.12689
58. World Health Organization (2016). Meeting Report: Technical Definitions of Shortages and Stockouts of Medicines and Vaccines. Available online at: http://www.who.int/medicines/areas/access/Meeting_report_October_Shortages.pdf?ua=1
59. World Health Organization (2017). WHO Model Lists of Essential Medicines. Available online at: http://www.who.int/medicines/publications/essentialmedicines/en/
60. Yang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., et al. (2016). Current situation, determinants, and solutions to drug shortages in Shaanxi Province, China: a qualitative study. PLoS ONE 11:e0165183. doi: 10.1371/journal.pone.0165183